Trial Profile
Endothelin Receptor Function and Acute Stress (End-Stress)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Bosentan (Primary)
- Indications Acute traumatic stress disorders
- Focus Therapeutic Use
- Acronyms End-Stress
- 30 Jan 2024 Planned End Date changed from 1 Jan 2024 to 1 Jan 2026.
- 30 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.
- 18 Jul 2022 Planned End Date changed from 1 Jul 2022 to 1 Jan 2024.